Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development [Seeking Alpha]
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 [Yahoo! Finance]
Enanta Pharma GAAP EPS of -$0.87, revenue of $15.1M [Seeking Alpha]
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.